Health Affairs' Jessica Bylander and Chris Fleming dive into the complex world of insulin pricing and recent efforts to control its costs for the millions of Americans with diabetes.
Read the Ahead of Print article on Medicare Advantage benchmarks by Michael Chernew and colleagues.
Related Links:
- Sanofi announces insulin price cap after actions by Eli Lilly and Novo Nordisk (NBC News)
- Why is insulin so expensive and difficult to cap? (AP News)
- California Picks Generic Drug Company Civica to Produce Low-Cost Insulin (Kaiser Health News)
- Insulin as Preventive Care: Why Not Eliminate Patient Cost Sharing? (Health Affairs Forefront)
Currently, more than 70 percent of our content is freely available — and we’d like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.